[HTML][HTML] Pancreatic cancer in 2021: What you need to know to win
V Tonini, M Zanni - World Journal of Gastroenterology, 2021 - ncbi.nlm.nih.gov
Pancreatic cancer is one of the solid tumors with the worst prognosis. Five-year survival rate
is less than 10%. Surgical resection is the only potentially curative treatment, but the tumor is …
is less than 10%. Surgical resection is the only potentially curative treatment, but the tumor is …
[HTML][HTML] Impact of exosome therapy on pancreatic cancer and its progression
Pancreatic cancer, one of the most aggressive tumors, has a dismal prognosis because of
the low rates of early identification, fast progression, difficulties following surgery, and the …
the low rates of early identification, fast progression, difficulties following surgery, and the …
[HTML][HTML] Oncological outcome of conversion surgery after preoperative chemotherapy for metastatic pancreatic cancer
T Hank, U Klaiber, U Hinz, D Schütte… - Annals of …, 2023 - journals.lww.com
Objective: To investigate the outcome of conversion surgery in patients with metastatic
pancreatic cancer (mPDAC) and to identify patients who may benefit from this approach …
pancreatic cancer (mPDAC) and to identify patients who may benefit from this approach …
FOLFIRINOX as initial treatment for localized pancreatic adenocarcinoma: a retrospective analysis by the Trans-Atlantic Pancreatic Surgery Consortium
QP Janssen, JL Van Dam… - JNCI: Journal of the …, 2022 - academic.oup.com
Background Large pragmatic studies of patients who received 5-fluorouracil with leucovorin,
irinotecan, and oxaliplatin ([m] FOLFIRINOX) as initial treatment for localized pancreatic …
irinotecan, and oxaliplatin ([m] FOLFIRINOX) as initial treatment for localized pancreatic …
Impact of complications after resection of pancreatic cancer on disease recurrence and survival, and mediation effect of adjuvant chemotherapy: nationwide …
AC Henry, JC Van Dongen, IWJM Van Goor… - BJS open, 2023 - academic.oup.com
Background The causal pathway between complications after pancreatic cancer resection
and impaired long-term survival remains unknown. The aim of this study was to investigate …
and impaired long-term survival remains unknown. The aim of this study was to investigate …
[HTML][HTML] Surgical treatment of pancreatic ductal adenocarcinoma
K Wei, T Hackert - Cancers, 2021 - mdpi.com
Simple Summary Surgery is the only potential cure for pancreatic ductal adenocarcinoma
and should always be combined with adjuvant chemotherapy or other multimodal treatment …
and should always be combined with adjuvant chemotherapy or other multimodal treatment …
Association of adjuvant chemotherapy in patients with resected pancreatic adenocarcinoma after multiagent neoadjuvant chemotherapy
Importance The total number of patients with pancreatic ductal adenocarcinoma (PDAC)
who receive neoadjuvant chemotherapy (NAC) is increasing. However, the added role of …
who receive neoadjuvant chemotherapy (NAC) is increasing. However, the added role of …
Evaluation of adjuvant chemotherapy survival outcomes among patients with surgically resected pancreatic carcinoma with node-negative disease after neoadjuvant …
Importance Neoadjuvant therapy (NAT) is rarely associated with a complete histopathologic
response in patients with pancreatic ductal adenocarcinoma (PDAC) but results in …
response in patients with pancreatic ductal adenocarcinoma (PDAC) but results in …
[HTML][HTML] PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC/LAPC: A biomolecular exploratory, phase II trial
J Du, C Lu, L Mao, Y Zhu, W Kong, S Shen, M Tang… - Cell Reports …, 2023 - cell.com
This is a phase II study of PD-1 blockade plus chemoradiotherapy as preoperative therapy
for patients with locally advanced or borderline resectable pancreatic cancer (LAPC or …
for patients with locally advanced or borderline resectable pancreatic cancer (LAPC or …
[HTML][HTML] FAT10 promotes chemotherapeutic resistance in pancreatic cancer by inducing epithelial-mesenchymal transition via stabilization of FOXM1 expression
J Zhu, J Zhao, C Luo, Z Zhu, X Peng, X Zhu, K Lin… - Cell Death & …, 2022 - nature.com
Pancreatic cancer (PC) is one of the deadliest malignant tumors, and its resistance to
gemcitabine chemotherapy is the primary reason for poor prognosis in patients. Ubiquitin …
gemcitabine chemotherapy is the primary reason for poor prognosis in patients. Ubiquitin …